title: Survival in gastric cancer in relation to postoperative adjuvant therapy and determinants.
abstract: To evaluate survival data in patients with gastric cancer in relation to postoperative adjuvant therapy and survival determinants
  
  
  
  A total of 201 patients (mean±SD age: 56.0±11.9 years, 69.7% were males) with gastric carcinoma who were operated and followed up at Lutfi Kirdar Kartal Training and Research Hospital between 1998 and 2010 were included in this retrospective study. Follow up was evaluated divided into two consecutive periods (before 2008 and 2008-2010, respectively) based on introduction of 3-D conformal technique in radiotherapy at our clinic in 2008. Data on patient demographics, clinical and histopathological characteristics of gastric carcinoma and the type of treatment applied after surgery [postoperative adjuvant treatment protocols including chemoradiotherapy (CRT) and chemotherapy (CT), supportive therapy or follow up without any treatment] were recorded. The median duration and determinants of local recurrence free (LRF) survival, distant metastasis free (DMF) survival and overall survival were evaluated in the overall population as well as with respect to follow up years [1998-2008 (n=127) vs 2008-2010 (n=74)].
  
  
  
  Median duration for LRF survival, DMF survival and overall survival were 31.9, 24.1 and 31.9 mo, respectively in patients with postoperative adjuvant CRT. No significant difference was noted in median duration for LRF survival, DMF survival and overall survival with respect to treatment protocols in the overall population and also with respect to followed up periods. In the overall population, CT protocols FUFA [5-fluorouracil (400 mg/m2) and leucovorin-folinic acid (FA, 20 mg/m2)] (29.9 mo) and UFT®+Antrex® [a fixed combination of the oral FU prodrug tegafur (flouroprymidine, FT, 300 mg/m2 per day) with FA (Antrex®), 15 mg tablet, two times a day] (42.5 mo) was significantly associated with longer LRF survival times than other CT protocols (P=0.036), while no difference was noted between CT protocols in terms of DMF survival and overall survival. Among patients received CRT, overall survival was significantly longer in patients with negative than positive surgical margin (27.7 mo vs 22.4 mo, P=0.016) in the overall study population, while time of radiotherapy initiation had no significant impact on survival times. Nodal stage was determined to be independent predictor of LRF survival in the overall study population with 4.959 fold (P=0.042) increase in mortality in patients with nodal stage N2 compared to patients with nodal stage N0, and independent predictor of overall survival with 5.132 fold (P=0.006), 5.263 fold (P=0.027) and 4.056 fold (P=0.009) increase in the mortality in patients with nodal stage N3a (before 2008), N3b (before 2008) and N2 (overall study population) when compared to patients with N0 stage, respectively.
  
  
  
  Our findings emphasize the likelihood of postoperative adjuvant CRT to have a survival benefit in patients with resectable gastric carcinoma.
authors: Radiation Oncology, Dr. Lutfi Kirdar Kartal Training and Research Hospital, 34890 Istanbul, Turkey.
authors: Sevgi
authors: S
authors: Ozden
authors: Radiation Oncology, Dr. Lutfi Kirdar Kartal Training and Research Hospital, 34890 Istanbul, Turkey.
authors: Zerrin
authors: Z
authors: Ozgen
authors: Radiation Oncology, Dr. Lutfi Kirdar Kartal Training and Research Hospital, 34890 Istanbul, Turkey.
authors: Hazan
authors: H
authors: Ozyurt
authors: Radiation Oncology, Dr. Lutfi Kirdar Kartal Training and Research Hospital, 34890 Istanbul, Turkey.
authors: Cengiz
authors: C
authors: Gemici
authors: Radiation Oncology, Dr. Lutfi Kirdar Kartal Training and Research Hospital, 34890 Istanbul, Turkey.
authors: Gokhan
authors: G
authors: Yaprak
authors: Radiation Oncology, Dr. Lutfi Kirdar Kartal Training and Research Hospital, 34890 Istanbul, Turkey.
authors: Huseyin
authors: H
authors: Tepetam
authors: Faculty of Medicine, Bezmialem Vakif University, 34093 Istanbul, Turkey.
authors: Alpaslan
authors: A
authors: Mayadagli
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D059186:Chemoradiotherapy, Adjuvant / Q000009:adverse effects / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D005743:Gastrectomy / Q000009:adverse effects / Q000401:mortality; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome; D014421:Turkey
keywords: Distant metastasis free survival; Gastric carcinoma; Local recurrence free survival; Overall survival; Postoperative adjuvant therapy
references: Gastroenterol Clin Biol. 2005 Jan;29(1):11-5
references: 15738890
references: Am J Clin Oncol. 1996 Apr;19(2):212-6
references: 8610653
references: N Engl J Med. 2006 Jul 6;355(1):11-20
references: 16822992
references: Clin Oncol (R Coll Radiol). 2006 Nov;18(9):663-8
references: 17100151
references: Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1073-80
references: 17905529
references: Radiother Oncol. 2009 Aug;92(2):176-83
references: 19586672
references: Cancer Radiother. 2010 Jan;14(1):19-23
references: 19963423
references: Cancer. 2010 Dec 15;116(24):5592-8
references: 20737569
references: Ann Surg Oncol. 2011 Apr;18(4):1060-7
references: 21107742
references: J Clin Oncol. 2011 May 1;29(13):1715-21
references: 21444866
references: Gastric Cancer. 2011 Jun;14(2):166-71
references: 21360132
references: Ann Surg Oncol. 2011 Jul;18(7):1869-76
references: 21246404
references: Radiother Oncol. 2012 Jan;102(1):51-5
references: 22178689
references: J Clin Oncol. 2012 Jan 20;30(3):268-73
references: 22184384
references: J Clin Oncol. 2012 Jul 1;30(19):2297-9
references: 22585690
references: J Clin Oncol. 2012 Jul 1;30(19):2327-33
references: 22585691
references: Radiother Oncol. 2012 Sep;104(3):361-6
references: 22985776
references: Eur J Cancer. 2014 Apr;50(6):1076-83
references: 24433843
references: J Clin Oncol. 1999 Dec;17(12):3810-5
references: 10577853
references: Cancer. 2000 Feb 15;88(4):921-32
references: 10679663
references: N Engl J Med. 2001 Sep 6;345(10):725-30
references: 11547741
references: Eur J Cancer. 2001 Sep;37(13):1642-7
references: 11527690
references: Ann Oncol. 2003 Sep;14(9):1373-7
references: 12954575
references: Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):353-9
references: 7836089
references: Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1279-85
references: 16099596